United States: New York Attorney General Enters Digital Health App And Privacy Enforcement Fray: Announces Three Settlements With Health And Fitness App Providers' Due To Efficacy Claims And Privacy Practices

On March 23, the New York Office of the Attorney General ("NY OAG") announced Assurances of Discontinuance ("Settlements") with three developers of health and fitness mobile apps. The Settlements appear to mark the NY OAG's first endeavor into investigating the efficacy claims and privacy practices of these types of apps. The Settlements are notable for, among other things, including requirements that the app providers (i) clearly state that their apps are not for medical use; (ii) cease collecting certain user information, such as device identifiers; (iii) obtain affirmative consent from users to collect and share other sensitive information; (iv) inform users that data collected by an app may not be protected under the Health Insurance Portability and Accountability Act ("HIPAA"); and (v) inform users that aggregated app data that does not identify users personally may be shared with third parties and that those third parties might be able to reidentify specific users.

The Heart & Fetal Heart Monitoring Apps

Two of the apps, known as Cardiio (provided by Cardiio, Inc.) and Runtastic (provided by Runtastic GmbH), were promoted as helping consumers monitor their heart rate using a phone's camera. Those apps were available in the Health & Fitness section of app stores, for free or a small fee, where the providers claimed the apps could turn an iPhone into a personal heart rate monitor. Both claimed that their app could accurately capture a person's heart rate, even after exercise. Cardiio also claimed it could estimate one's life expectancy using the data the app collected.

Neither Cardiio nor Runtastic required users to expressly consent to the app's data collection practices, appearing to rely on notice through making a privacy policy available and implied consent. Among other things, the Cardiio app could collect GPS information and Runtastic unique device identifiers. Neither expressly disclosed that fact. Runtastic also had a live tracking feature that could share your location with third parties.

The third app, known as My Baby's Beat-Baby Heart Monitor App, was provided by Matis Ltd. The app was the most popular paid app in the Apple App Store medical category in 2016, and had as its logo a baby inside a stethoscope. Using only a phone's microphone, Matis claimed in the Apple App Store that "you can listen to your baby's heartbeat and movements, just like a Fetal Heart Monitor." In the Google Play store, Matis claimed that "[i]nstead of buying a home Doppler you can turn your smartphone in a Fetal heart monitor, using ONLY the PHONE'S MICROPHONE and a pair of headphones."

The data the app collected included global unique device identifiers, user feedback, an engagement score, and recordings. Though a privacy policy was available to users of the My Baby's Beat app, the policy did not disclose that that information was collected. The policy did disclose that data might be shared on an aggregated basis, but did not disclose risks associated with that practice.

In pursuing these investigations and settlements, the NY OAG relied on NY statutes prohibiting "deceptive acts or practices in the conduct of business" and "false advertising in the conduct of any business." N.Y. Gen. Bus. Law §§ 349, 350. While the targets neither admitted nor denied the NY OAG finding, the NY OAG Settlement with each is premised on the NY OAG's claims that "[m]arketing a Health Measurement App without substantiation that it accurately measures what it purports to measure, and without fully and clearly disclosing privacy practices, constitute deceptive trade practices." The NY OAG's allegations regarding both parts of this allegation are noteworthy. The first part – regarding claims of what the app can accomplish – stands as a warning itself for all providers of Life Style or Health & Fitness apps to ensure claims indeed are accurate. The second part – regarding data collection practices – if continued to be pressed by the New York and OAG, could result in a significant change in app data collection and sharing practices.

The Advertising Claims

With respect to the app providers' claims, the NY OAG in each Settlement noted that heart and fetal heart rate monitors generally are regulated as Class II medical devices by the FDA. Class II devices are higher risk devices than Class I devices, and "require greater regulatory controls to provide reasonable assurance of the device's safety and effectiveness."

The NY OAG alleged that claims made by Cardiio and Runtastic conveyed a "net impression" that the applications could accurately measure and monitor heart rates of users engaged in vigorous exercise – akin to heart rate monitors. But the applications did not provide sufficient evidence to substantiate such claims. In fact, it was not clear that the applications had been tested on users engaged in vigorous exercise.

As for the My Baby's Beat app, the NY OAG alleged that Matis informed users they could use My Baby's Beat instead a fetal heart monitor or Doppler device. This claim was made despite the absence of FDA approval or clearance, and despite Matis not having conducted testing to compare its application to fetal heart monitors or Doppler devices. The New York OAG found all three apps could potentially harm consumers by providing inaccurate or misleading results.

In the Settlements, each of the app providers agreed to provide clear and prominent warnings. Matis revised its descriptions on app stores to state that My Baby's Beat app is not to be used for medical decisions of any kind. The providers of the heart monitor apps added warnings that those apps are not for medical use, and not cleared or approved by the FDA. As for the fetal heart monitor app, the provider also changed the name and logo of the app, and agreed to move the app from the "Medical" to "Lifestyle" app category.

The Privacy Claims

All three apps had privacy policies that appeared to rely on consumer consent by default. The Settlements state that the heart rate monitor app providers "maintain[ed]" privacy policies while the fetal heart monitor app providers made a privacy policy "available" to users. None appear to have required express user consent.

The NY OAG also found individual data handling and disclosure practices by the app providers troubling under New York's consumer deception laws. Cardiio, for instance:

  1. could collect GPS location "which, when combined with other information about a user, may be personally identifiable information";
  2. could disclose aggregated data to third parties, but failed to disclose "the risk that third parties who receive such data . . . may reidentify specific users"; and
  3. did not disclose that "personal health information" (such as heart-related conditions) collected, stored and shared by Cardiio "may not be protected under the Health Insurance Portability and Accountability Act ('HIPAA')."

The Runtastic and Matis apps collected device identification information, which the New York OAG termed "personally identifiable information" in those Settlements.

In support of its claims that the risk of reidentification of aggregated data should be disclosed, the NY OAG in each Settlement cites papers by Prof. Paul Ohm and Prof. Latanya Sweeney that cast doubt on the efficacy of anonymization techniques, especially among combined data sets. See Paul Ohm, Broken Promises of Privacy: Responding to the Surprising Failure of Anonymization, 57 UCLA L. Rev. 1701 (2010); Latanya Sweeney, Only You, Your Doctor, and Many Others Know, Technology Sci. (2015).

The NY OAG also criticized a statement in the Cardiio privacy policy that it could disclose user information to third parties if it believed in good faith that disclosure was "reasonably necessary to protect the property or rights of Cardiio, third parties or the public at large." The Cardiio Settlement states that "[t]his conferred virtually unlimited discretion on Cardiio, Inc. in disclosing users' personal information."

In the Settlements, the heart monitor app providers agreed to obtain express consent to their data handling practices from users. This includes requiring a user to scroll through the policy and affirmatively click on a consent button. The Cardiio policy going forward needs to, among other things, clearly and prominently disclose the above risks. Runtastic made similar commitments, as well as agreeing to adopt a right-to-be-forgotten mechanism. Matis, the fetal heart monitor app provider, among other things, agreed to stop collecting user device ids.

Take-Aways

The NY OAG's actions exemplify the increased enforcement risk for app providers from state attorneys general and other non-federal regulatory actors. With respect to health-related mobile apps, the NY OAG estimates there are more than 165,000 such apps available for download on smartphone devices. Many of these app providers are not covered by HIPAA and may presume (often incorrectly) that they are immune from FDA or state enforcement.

While the Federal Trade Commission ("FTC") has also shown interest in regulating this space, these recent NY OAG Settlements may represent a shift from federal agencies to state attorneys general in the regulation of claims and data handling procedures made by health-related apps. Although questions remain concerning the FTC's ability to regulate privacy practices under Section 5 of the Federal Trade Commission Act, the NY Attorney General, Eric T. Schneiderman, stated in announcing the Settlements that his office would "not hesitate to take action against developers that disseminate unfounded information that is both deceptive and potentially harmful to every day consumers."

Going forward, mobile app and software developers should evaluate how individual states could monitor their claims and privacy practices in addition, or in lieu of, federal regulators. Companies operating in health-related fields especially should review the claims they disseminate and the way they engage with consumer privacy data in light of the ever-developing regulatory environment.

Links:

In re: Cardiio, Inc., Assurance No.: 16-173

In re: Matis Ltd., Assurance No.: 16-101

In re: Runtastic GmbH, Assurance No.: 16-174

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.